[Correspondence] Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer

We read with great interest the OVHIPEC-1 study by S Lot Aronson and colleagues1 published in The Lancet Oncology, which addresses the application of hyperthermic intraperitoneal chemotherapy (HIPEC) during interval surgery in ovarian cancer treatment. The study’s findings regarding HIPEC’s impact on both progression-free survival and overall survival are of paramount importance within the context of the ongoing debate surrounding the role of HIPEC in ovarian cancer management. However, we wish to raise some concerns regarding the study’s design and suggest conducting subgroup analyses to further elucidate the patient population that stands to benefit most from this intervention.